Spondyloarthropathies News

Samsung Bioepis and Abbvie have reached a global settlement agreement regarding the commercialization of SB5, the proposed adalimumab biosimilar for Humira, according to a press release.

Patients with arthritis who are younger, have rheumatoid factor positivity and demonstrate higher disease activity at baseline are at an increased risk for experiencing methotrexate failure due to inefficacy, according to findings published in Arthritis Care & Research.

Anti–TNF therapy is effective in patients with ankylosing spondylitis and psoriatic arthritis at 4 months, and becomes progressively more effective during the next 3 years, with a drug retention rate of approximately 60%, according to findings published in the Journal of Clinical Rheumatology.

Depression prevalence is high among patients with axial spondyloarthritis, and is associated disease activity, functional impairment, lower income and lack of exercise, according to findings published in the Annals of the Rheumatic Diseases.

Sandoz received a positive opinion the European Medicines Agency’s Committee for Medicinal Products for Human Use for its proposed infliximab biosimilar for the treatment of all indications of its reference product across rheumatology, dermatology and gastroenterology, according to a manufacturer release.

The FDA has approved changing the boxed labeling on certolizumab pegol to include data demonstrating a negligible-to-low risk for drug transfer through placenta and a minimal risk for transfer through breast milk among women with chronic inflammatory diseases.

The use of biologic medications for autoimmune diseases prior to or during pregnancy is not associated with an increased risk for preterm delivery or infants that are small for gestational age, according to findings published in the Annals of the Rheumatic Diseases.

The evaluation of anti-CD74 IgA antibodies is not specific enough to provide a significant benchmark for the diagnosis of axial spondyloarthritis in patients younger than 45 years who present with early back pain, according to findings published in Arthritis Research and Therapy.

Patients with new-onset inflammatory back pain have just a 30% chance of developing spondyloarthritis during the next 10 years, and a 43% probability of back pain resolution, according to findings published in Arthritis and Rheumatology.

Patients with early inflammatory polyarthritis diagnosed within the new millennium experienced improved disease activity, compared with those diagnosed during the early 1990s, according to findings published in the Annals of the Rheumatic Diseases.